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OBJECTIVES The purpose of this study was to create an automated surveillance tool for reporting the
incidence, prevalence and processes of care for patients with heart failure.
BACKGROUND Previous epidemiologic studies suggest that the increasing prevalence of heart failure is a
consequence of improved survival coupled with minimal changes in disease prevention.
Developing new, efficient methods of assessing the incidence and prevalence of heart failure
could allow continued surveillance of these rates during an era of rapidly changing treatments
and health care delivery patterns.
METHODS Using administrative data sets, we created a definition of heart failure using diagnosis codes.
After adjustment for patients leaving our health system or death, we derived the incidence,
prevalence and mortality of the population with heart failure from 1989 to 1999.
RESULTS A total of 29,686 patients of all ages, 52.6% women and 47.4% men, met the definition of
heart failure. Mean ages were 71.1  14.5 for women and 67.7  14.4 for men, p  0.0001.
Race proportions were 50.5% white, 44.6% African American and 4.9% other race. Incidence
rates were higher in men and African Americans across all age groups. There was an annual
increase in prevalence of 1/1,000 for women and 0.9/1,000 for men, p  0.001 for both
trends.
CONCLUSIONS Through the feasible and valid use of automated data, we have confirmed a chronic disease
epidemic of heart failure manifested primarily by an increase in prevalence over the past
decade. Our surveillance system mirrors the results of epidemiologic studies and may be a
valid method for monitoring the impact of prevention and treatment programs. (J Am Coll
Cardiol 2002;39:60–9) © 2002 by the American College of Cardiology
Previous cross-sectional studies from large data sets have
shown increases in the point prevalence of congestive heart
failure (CHF) in the U.S. and Europe since the 1970s (1–7).
Prospective cohort studies have identified age, coronary
artery disease, valvular disease and poorly controlled hyper-
tension as major determinants of CHF (8,9). However,
selection biases for entry into prospective cohort studies and
randomized trials limit generalizability due to underrepre-
sentation of African Americans, women and the elderly
(10). Recent analyses of the National Health And Nutrition
Examination Survey (NHANES) II have evaluated cross-
sectional data with future follow-up to generate CHF point
prevalence estimates of 1.04% by subject self-report and
1.78% by clinical evaluation, including chest X-ray, in the
U.S. population between the ages of 25 and 75 (6,7). All of
these sources of information taken together, however, are
inadequate to evaluate the impact of CHF on integrated
health systems, which provide both acute and chronic care
on a long-term basis. The purpose of this investigation, the
Resource Utilization Among Congestive Heart Failure
(REACH) study, was to demonstrate the feasibility of
creating an information infrastructure to report the epide-
miology of CHF and its impact on resource utilization
within an integrated health system.
METHODS
Setting. Henry Ford Hospital is a 903-bed tertiary care
center located in the Detroit metropolitan area and receives
patients whose care is provided primarily within Henry Ford
Health System (HFHS), a vertically integrated, mixed
model managed care organization (MCO), which includes
urban and suburban satellite clinics in Southeast Michigan
(11). The HFHS maintains a data warehouse comprised of
administrative, clinical and encounters tables. Approxi-
mately 85% of HFHS patients are aligned to the Henry
Ford Medical Group, a 1,000-physician multispecialty
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group and receive the majority, if not the entirety, of their
care within HFHS. Health Alliance Plan (HAP), the
primary MCO for HFHS, maintains comprehensive ad-
ministrative tables for encounters within HFHS and hos-
pitals nationwide. This setting provided an opportunity to
develop search strategies to identify and follow patients with
medical conditions of interest over time.
Case definitions. An index case of CHF was defined as an
aligned patient who had accumulated at least two outpatient
encounters (emergency department, urgent care or clinic) or
one hospitalization coded for CHF. The 9th International
Classification of Diseases, Clinical Modification (ICD-9-
CM) codes for CHF used were previously validated in CHF
case findings and included the following: 428.XX, 398.91,
402.01, 402.11, 402.91, 404.00, 404.01, 404.03, 404.10,
404.11, 404.13, 404.90, 404.91, 404.93 (12,13). Of note,
the codes 404.00, 404.10 and 404.90 were included to
capture patients with combined heart and renal failure.
Hospitalizations for CHF required diagnosis-related group
(DRG) 127 or one of the above ICD-9-CM codes in the
principal position. In addition, patients with 1 hospital
discharge coded with DRG 124 and one of the ICD-9-CM
codes in the preceding text in the principal diagnosis
position were included. This included patients whose prin-
cipal diagnosis was CHF but, because of a diagnostic
catheterization during the stay were assigned to DRG 124
instead of 127. This search strategy excluded those patients
whose only code for CHF was in the secondary position.
For hospital admissions, DRG codes were assigned by
professional coders and approved by the attending physi-
cian. During outpatient visits, the attending physician
assigned the codes at the time of the encounter. Death was
ascertained by death within an HFHS facility, death con-
firmed by State of Michigan Death Registry tapes or the
National Center for Health Statistics Death Index. We
observed a 99% vital status ascertainment after five or
more years from an index year. Each patient had a unique
medical record number that avoided double counting.
Data management. We applied the index case search
definition to all aligned HFHS patients and all HAP
patients beginning in the calendar year 1989. Among cases
found in 1989, it was assumed that the ratio of index to
prevalent cases was 1 to 1. For each subsequent year, index
cases were queried for the presence or absence of any
medical care delivered. If no activity was found, a search for
death records from the three sources listed above was done.
If death was not found, individuals were considered to be
temporarily out of HFHS or HAP and were kept in a
dataset for continued prospective resource utilization or
death. If in a subsequent year, a patient was found to be
active or dead, the prior year prevalence pool was amended
to reflect the presence of that individual, thus accounting for
patients who exited the HFHS. Patients with established
CHF who entered the system were counted as index cases
once the ICD-9-CM definition was met. Patients without
CHF entering the system were counted in the denominator
of HFHS patients for that year. Once declared an index
case, CHF was considered irreversible and present until
death. This methodology was unable to detect and confirm
reversible cases of CHF including myocarditis, metabolic
cardiomyopathies and cases where revascularization im-
proved cardiac function to a degree where CHF could be
considered cured. It was expected that these cases were
sufficiently uncommon as to affect the main results.
Data validation. To check on the positive predictive value
of the index case definition by ICD-9-CM coding, a case
validation procedure was carried out. A 1% random sample,
n  271 (58.3% women, 41.7% men) of REACH subjects
was taken, and chart abstraction was performed with explicit
criteria applied by the Framingham and NHANES I
definitions of CHF (7,10). A total of 172 (63.5%) subjects
met the Framingham definition, and 151 (55.7%) subjects
met the NHANES definition (score 3) of CHF. Of those
who met any definition of CHF (n  200, 73.8%), the
mean ejection fraction was 42.5  16.0%. Because both the
Framingham and NHANES I definitions were designed for
populations free of disease and not for active HFHS
patients, a second validation procedure was carried out. Two
physicians, one internist and one cardiologist, were given a
portion of the sample comprised of patients under their care
and performed chart abstraction for confirmation of CHF
by chart notes, with classification according to the New
York Heart Association (NYHA). Of the sample reviewed
(n  263, 44.1% women, 55.9% men), 82.9% of cases were
confirmed to have CHF. Of those with validated CHF at
the time of last clinical encounter, the proportions of
NYHA classes were as follows: class I, 25.1%; class II,
36.1%; class III, 28.9% and class IV, 9.9%. Of those without
CHF mentioned in the chart notes: 60.0% had dyspnea
listed, and 85.0% had a primary cardiac diagnosis such as
coronary artery disease, atrial fibrillation, prior cardiac
surgery or structural heart disease. That is, while not having
CHF explicitly listed in the chart, these patients received
ICD-9-CM codes and had the cardiac substrate and asso-
ciated findings to support the presence of CHF. Only 5.0%
had no mention of cardiovascular disease in the chart notes.
Most likely, this overestimation was counterbalanced by the
previously described community underestimation of CHF
Abbreviations and Acronyms
CHF  congestive heart failure
DRG  diagnosis related group
HAP  Health Alliance Plan
HFHS  Henry Ford Health System
ICD-9-CM  9th International Classification of
Diseases, Clinical Modification
MCO  managed care organization
NHANES  National Health And Nutrition
Examination Survey
NYHA  New York Heart Association
REACH  Resource Utilization Among Congestive
Heart Failure study
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by hospitalization ICD-9-CM codes described in the Cor-
pus Christi Heart Project (14). Thus, investigators felt that
the study definitions and population characteristics would
yield valid point estimates on the epidemiology of CHF,
and statistical analysis of the entire population was under-
taken.
Statistical analysis. Univariate statistics were reported as
proportions or means, and comparisons were made with
chi-square or analysis of variance, as appropriate. Incidence
and prevalence were reported in terms of total number of
HFHS patients for that given year. This adjusted for
denominator change, which was small given the stability of
the HFHS during the study period. Incident cases excluded
those who had been identified in prior years. Prevalent cases
included: 1) those identified in prior years who were active
in the HFHS and alive, and 2) those who were inactive in
that year but found to be dead or alive in future years. This
prevented the problem of migrating patients changing either
the numerator or denominator. Age- and gender-
adjustment of rates was carried out using direct standard-
ization to the 1994 (midpoint) age and gender structure of
the HFHS population (Table 1). Cox regression was used to
compare adjusted survival among groups of interest. Statis-
tical significance was chosen at the alpha 0.05 level.
RESULTS
Baseline characteristics. Age, gender, race and insurance
status for the 29,686 individuals identified with CHF are
given in Table 2. Women comprised 52.6% of the study
group and contributed similar mean person-months to
REACH as men, 24.3  15.4 mean person-months and
23.9  13.8 mean person-months , p  0.2, respectively.
Likewise, African Americans and whites contributed simi-
larly to the cohort, 24.6  13.1 mean person-months and
24.8  18.8 mean person-months, p  0.62. The race
group labeled “other” was comprised of women and men in
the following categories: Hispanic, Native Americans,
Asian, Middle Eastern and “unknown or unstated.” Of
note, the mean age of index cases was older for women than
it was for men across all race groups by an average of 3.4
years. In addition, the types of insurance carriers were
statistically different for women and men, with 10,106
(64.7%) and 8,293 (60%) having Medicare, parts A and B,
listed as their primary forms of insurance, respectively, p 
0.00001. This reflected the older mean age of women and
proportional increase in eligibility for Medicare. Of note,
38.0% of all patients in REACH had a non-Medicare
primary form of insurance, predominately HAP, the HF-
HS’s managed care organization. The HFHS denominator
of individual patients consisted of 2,928,286 (57%) women
and 2,209,057 (43%) men.
Incidence and prevalence. The overall age- and gender-
adjusted incidence and prevalence of CHF are given by
one-year intervals in Figures 1 and 2. There was no secular
trend observed for incidence. However, Figure 2 displays
linear trends for an increase in the number of prevalent cases
adjusted for the HFHS population with an average increase
of 1.0/1,000 for women (3.7 to 14.3/1,000) and 0.9/1,000
for men (4.0 to 14.5/1,000), p  0.0001 for both trends.
This represented a tripling of prevalence over the 11-year
study period.
Gender and race differences in incident cases by age
grouping are shown in Figures 3 and 4. In REACH, men
predominated in all incident age groups when adjusting for
the denominator of all HFHS patients, p 0.0000001 (Fig.
3). While African Americans comprised 44.6% of the study
sample, the rates of new cases of heart failure were consis-
tently higher among African American HFHS patients than
they were for whites or other race groups, p  0.0000001
(Fig. 4). The “other” race group, comprised mainly of those
with “unknown or unstated” race, was relatively equally
distributed among the age groupings.
Mortality. Case fatality rates for incident and prevalent
cases are displayed in Figure 5. Mortality for 1999 index
cases was checked through the first quarter of 2000. The
case fatality rate per year, shown in Figure 5, displays an
inception cohort effect. This means that some patients
identified in 1989 to 1993 likely had a shorter lead time in
the database until death since the true onset of CHF may
have been before 1989. The average, overall case fatality rate
per year was 17.1% and 15.1% for incident and prevalent
cases, respectively, p  0.0000001. The overall median
survival was 4.2 (95% confidence interval: 4.1 to 4.3) years.
The median survival was longer for women compared with
men, 4.5 versus 3.7 years, p  0.00001. Age-adjusted
survival was also significantly better for women compared
with men, p  0.0001 (Fig. 6). In addition, age- and
gender-adjusted mortality was the best for whites, interme-
diate for African Americans and least favorable for other
race groups, p  0.0001 (Fig. 7). Age at the time of
diagnosis was a clear discriminator of gender- and race-
adjusted survival as depicted in Figure 8. The five-year
survival rate for those 85 years diagnosed with CHF was
20%.
Table 1. Age Structure of the Henry Ford Health System
General Population Taken From a Random Sample (n  3,195)
of Enrollees in 1994, the Midpoint of REACH Time Frame
Age in
Years Women Men Total
0–9 60 73 133
10–19 28 30 58
20–29 64 39 102
30–39 80 73 153
40–49 75 64 139
50–59 55 65 120
60–69 59 53 112
70–79 61 42 103
80–89 43 18 61
90–99 14 4 18
100–109 1 0 1
Counts are expressed per 1,000 health system patients and rounded to the nearest
whole number.
REACH  Resource Utilization Among Congestive Heart Failure study.
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DISCUSSION
Changing heart failure epidemiology. We found that
incidence rates of CHF were variable from year to year with
no clear secular trend. However, we found a significant rise
in prevalent cases from 1989 to 1999. Mortality rates were
consistently higher for incident cases than they were for
prevalent cases, presumably because only the healthiest
patients survived long enough to enter the pool of prevalent
patients. We attribute the rising prevalence in REACH to:
1) compilation methods and enhanced case identification
with ICD-9-CM codes screened over a long time period, 2)
inclusion of minorities with higher rates of CHF not
captured in prior epidemiologic studies, and 3) improved
survival among patients with CHF (15–17). Our findings
are consistent with other studies in supporting the notion
that the aging of the population and therapeutic advances
are leading to an epidemic of CHF (2,6). The REACH
study extends the observations of previous epidemiologic
studies by showing that the prevalence pool is increasing at
a rate of approximately 1.0/1,000 HFHS patients per year.
While in our study sample, women were predominant
(65.6%) in the group85 years, but, when adjusting for the
denominator of all HFHS patients, men consistently had
higher incident rates yet poorer survival compared with
women.
Incidence. Our incidence rates were consistent with the
few epidemiologic sources of data on incidence through the
1990s (9,15,16). Framingham results during the 1980s
reported an incidence of CHF among persons age 45
years of 4.7 cases/1,000 in women and 7.2 cases/1,000 in
men (9). This is in contrast with REACH, where the
denominator was HFHS patients of all ages and the annual
incidence was 5.3/1,000 in women and 5.5/1,000 in men.
Our finding of a male predominance in incidence confirms
findings published from Framingham and other studies
(9,17). However, there may be an underrepresentation of
the problem of heart failure in men (5). Previous studies of
asymptomatic left ventricular dysfunction have found men
are twice as likely as women to have asymptomatic disease.
In addition, CHF is more common in men when a clinical
examination or echocardiography has been used to define
the condition (2). Therefore, women may have been more
Table 2. Age, Gender, Race and Major Insurance Carrier for 29,686 Patients With CHF in the
REACH Study
Characteristics Women Men p Value
Total n (incident and
prevalent cases)
15,626 (52.6) 14,060 (47.4) 0.0001
White, n  14,945 7,692 (51.2% of n) 7,307 (48.8% of n) 0.0001
Age 73.7  13.3 69.2  13.6 0.0001
Total person-months 189,128.2 176,241.1 —
Mean person-months 25.0  27.5 24.5  27.6 0.32
Medicare A & B 5,154 (67.0) 4,257 (58.3) 0.0001
Health Alliance Plan HMO 1,514 (19.7) 1,636 (22.4) 0.00005
Blue Cross Blue Shield 325 (4.2) 547 (7.5) 0.0001
Other HMO 54 (0.7) 68 (0.9) 0.17
Commercial Insurance 113 (1.5) 193 (2.6) 0.0001
Medicaid 113 (1.5) 107 (1.5) 0.96
Unknown 419 (5.4) 499 (6.8) 0.0003
African American, n  13,121 7,182 (54.1% of n) 6,050 (45.9% of n) 0.0001
Age 68.1  15.1 65.6  15.0 0.0001
Total person-months 175,446.1 145,418.8 —
Mean person-months 24.8  28.6 24.4  27.9 0.41
Medicare A & B 4,470 (62.2) 3,619 (59.8) 0.005
Health Alliance Plan HMO 1,182 (16.5) 932 (15.4) 0.09
Blue Cross Blue Shield 310 (4.3) 425 (7.0) 0.0001
Other HMO 310 (4.3) 259 (4.3) 0.99
Commercial Insurance 60 (0.8) 72 (1.2) 0.02
Medicaid 349 (4.9) 295 (4.9) 0.98
Unknown 501 (7.0) 448 (7.4) 0.37
Other race, n  1,455 752 (51.7% of n) 703 (48.3% of n) 0.07
Age 73.7  13.3 70.7  14.0 0.0001
Total person-months 9,275.5 9,236.0 —
Mean person-months 12.7  20.9 13.5  20.7 0.43
Medicare A & B 482 (64.1) 417 (59.3) 0.06
Health Alliance Plan HMO 100 (13.3) 113 (16.1) 0.13
Blue Cross Blue Shield 44 (5.9) 46 (6.5) 0.58
Other HMO 22 (2.9) 22 (3.1) 0.82
Commercial Insurance 9 (1.2) 13 (1.8) 0.31
Medicaid 24 (3.2) 28 (4.0) 0.42
Unknown 71 (9.4) 64 (9.1) 0.82
HMO  health maintenance organization; REACH  Resource Utilization Among Congestive Heart Failure study.
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likely to manifest symptomatic CHF and, hence, be cap-
tured by the REACH methodology, which requires ICD-
9-CM codes generated by face-to-face physician encounters
or hospitalizations. The dominance of African Americans in
incidence rates among HFHS patients confirmed earlier risk
estimates from smaller studies (5). As previously shown, in
general African Americans have a 50% to 75% excess rate of
new heart failure as non-African Americans.
Prevalence. Our prevalence rates were consistent with
prior cross-sectional studies, which suggested a rise in the
prevalence of CHF in the U.S. when assessed at different
time periods (NHANES I 1971 to 1974, NHANES II
1976 to 1980) (6,7). These time periods, however, almost
certainly do not reflect the widespread use of vasodilators
and beta-blockers, which have been shown to reduce CHF
mortality. Hence, our finding of a sharp rise in prevalence
through the 1990s represents new information pointing to a
larger chronic disease epidemic on the basis of prevalence
than has been previously described. We acknowledge that
our methods report “prevalence” in the early years of data
Figure 1. Age- and gender-adjusted incidence of congestive heart failure in an integrated health system from 1989 to 1999. p  0.05 for linear trend in
both groups.
Figure 2. Age- and gender-adjusted prevalence and of congestive heart failure in an integrated health system from 1989 to 1999. For both men and women,
the prevalence of congestive heart failure has tripled over the decade of the 1990s. p  0.0001 for linear trend in women and men.
64 McCullough et al. JACC Vol. 39, No. 1, 2002
Heart Failure Epidemic January 2, 2002:60–9
acquisition including 1989 as a starting point and up to
approximately 1995 as a representation of cumulative inci-
dence. It is only after all existing cases have been captured
using ICD-9-CM codes that true prevalence can be appre-
ciated. The reported, annualized point prevalence of CHF
in REACH was 10.5/1,000 in women and 10.9/1,000 in
men. This is considerably greater than the age-adjusted
point prevalence of CHF reported from Framingham dur-
ing the 1980s (7.7/1,000 in women and 7.4/1,000 in men)
(9). Our findings suggest that the more comprehensive
ICD-9-CM search algorithm and use of inpatient and
outpatient encounters in REACH have overcome the un-
derreporting of CHF prevalence in communities by the use
of hospitalization discharge codes alone (14). In addition,
prevalence estimates from Framingham represent a denom-
inator of adults 45 years, unlike REACH, which used a
denominator of HFHS patients of all ages (Table 3).
Patients 45 years (n  2,006 [6.8%]) were retained for
two reasons: 1) to allow representation of younger individ-
uals with CHF not included in prior epidemiologic studies,
and 2) to provide a database for case finding of young
patients with CHF in the HFHS for future studies. When
compared with multiple large-scale epidemiologic studies of
prevalence through the 1990s however, the prevalence
found in our study is in line with the 9.0/1,000 to 15.0/
1,000 rates reported (2,5,14,18,19).
Survival. The overall median survival for CHF in REACH
was 4.5 versus 3.7 years for women and men, respectively.
These survival times are longer than 3.2 and 1.7 years in
women and men, respectively, previously reported in the
652 persons with CHF from the combined Framingham
Heart and Offspring study cohorts (n 9,405 denominator)
(5). These differences should be noted in light of the similar
mean ages at diagnosis in REACH (69.5  14.5 years) and
Framingham (70.0  10.8 years) (5). However, one must
consider that fully 39.7% and 12.7% of REACH patients
developed CHF75 years and85 years, respectively. The
median survival for those 65 years in REACH was six
Figure 4. Incident cases of heart failure in race groups by age group in the Resource Utilization Among Congestive Heart Failure study. *p  0.0000001
for African American (black bars) versus white (white bars) or other race (striped bars) groups.
Figure 3. Incident cases of heart failure in men (white bars) and women (black bars) by age group in the Resource Utilization Among Congestive Heart
Failure study (REACH). *p  0.0000001 for all pairwise comparisons.
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years. This is longer than previously reported in Framing-
ham and other epidemiologic studies, supporting the case
that improved therapies for myocardial infarction are creat-
ing more cases of CHF and that improved treatment of
CHF is prolonging the survival of these patients (5,20–22).
Alternatively, differences in case definitions in REACH and
other studies may have accounted for the survival differences
seen. The annual case fatality rates of 17.1% and 15.1% in
incident and prevalent cases in REACH are much lower
than the 23% to 50% mortality rates reported from studies
of recently hospitalized patients with CHF (17,23). This is
likely due to the fact that REACH included patients
identified as outpatients, with lesser degrees of CHF and,
hence, is more reflective of the true annual mortality rate of
this condition.
Study limitations. We acknowledge that there are multiple
limitations to our study. Using ICD-9-CM codes as the
basis for a definition of CHF does not equate to the
stringent criteria used in Framingham, NHANES or the
opinion of clinicians as demonstrated and discussed in our
data validation section. Hence, our study is hampered by
misclassification bias. This bias is almost certainly nondif-
Figure 5. Case fatality rate per year among incident (white bars) and prevalent (black bars) cases in the Resource Utilization Among Congestive Heart
Failure study. The higher mortality among incident cases relative to prevalent cases before 1994 most likely represents lead-time bias in the index case
ascertainment algorithm. *p  0.01.
Figure 6. Age- and race-adjusted mortality for men and women with congestive heart failure in an integrated health system, 1989 to 1999. p  0.0001.
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ferential and would bias any analytic conclusion to the null
hypothesis. For example, a null hypothesis could be that
prevalence is not changed over time. Our methods indicate
that any bias towards this null makes the case for a rise in
prevalence even stronger. It is possible that prevalent cases
were counted as incident cases if there was a prolonged
period (several years) without encounters coded for CHF
prior to 1989; however, this incidence-prevalence bias is
unlikely to affect point estimates in later years given the
reported survival duration in our study. It was also possible
that a differential exit of CHF or healthy patients from the
system who remain alive could shift the denominator and
change both incidence and prevalence rates. Another source
of bias would be a secular trend over time for the HFHS to
take in patients with greater comorbidities or recruit more
patients with CHF. The HFHS started a cardiac transplant
service in 1985 and maintained it throughout the study
period with no change in numbers of heart failure specialists
and no change in the approximately 15 annual transplants
performed. Furthermore, we are unaware in any shift in
case-mix within the HFHS and acknowledge this is an area
worthy of future study. Our study did not have the resources
to evaluate full decision statistics including the negative
predictive value of the ICD-9-CM code algorithm. An
example evaluation would call for a random chart review of
5,000 HFHS charts to yield an expected 100 patients with
and 4,900 without CHF, respectively (assuming a point
prevalence of 2%). Random sample sizes smaller than
5,000 would likely inflate the negative predictive value
because of the low point prevalence of CHF in the HFHS
population. Extrapolation of our results may be limited by
the relatively high (20.9%) managed care component of the
study sample. Conversely, having a mixed population of
fee-for-service, managed care, Medicaid and underinsured
patients is the strength of REACH not seen in other
epidemiologic studies. Generalizability to the U.S. or West-
ern European countries is limited due to the high propor-
tion of African Americans in our sample. Conversely,
REACH represents the largest cohort of African Americans
with CHF in the medical literature today, which adds to the
observations taken from small numbers of African Ameri-
cans in cross-sectional and cohort studies (5,13,15,23).
Study implications. The REACH study adds to current
insights into the epidemiology of CHF in the following
ways: 1) it demonstrated a feasible, automated, “turn-key”
methodology that may be replicated by other health sys-
tems; 2) it included information on CHF across all age
ranges and was not restricted to those 65 years (e.g.,
studies from Medicare data); 3) it comprised CHF cases
identified on an in-patient and outpatient basis and, hence,
was more useful in describing the global aspects of the
problem than studies of hospitalized patients only; 4) it
included a large proportion of African Americans not
previously captured in U.S. or European epidemiologic
Figure 7. Age- and gender-adjusted mortality by race for patients with congestive heart failure in an integrated health system, 1989 to 1999. *p  0.0001
for all pairwise comparisons.
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studies or randomized trials; and 5) although this will require
validation, REACH presumably included patients with both
systolic and diastolic dysfunction forms of CHF and, hence, is
expected to be a more complete description of the full spectrum
of CHF outcomes than those from randomized trials of left
ventricular dysfunction alone (2,24–27).
Conclusions. We conclude that, by use of ICD-9-CM
codes and automated sources of data, the epidemiology of
CHF can be described within health systems. Through the
1990s, there has been a growing epidemic of CHF preva-
lence captured by ICD-9-CM codes. Aging of the U.S.
population almost certainly is the most important factor in
this evolving epidemic. Consistent with studies from earlier
decades, men have higher incidence rates but poorer sur-
vival. Women now predominate the CHF prevalence pool
and appear to present with CHF at older ages. The CHF
epidemic extends to African Americans, who have signifi-
cantly higher rates of new onset CHF and suffer a poorer
long-term survival compared with whites. The techniques of
identifying incident and prevalent cases in REACH may
provide an important tool for cost-effectively evaluating the
impact of new treatments on large populations of patients.
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Figure 8. Age-stratified mortality, adjusted for gender and race, for patients with congestive heart failure in an integrated health system, 1989 to 1999. Age
is taken at the time of diagnosis of heart failure. p  0.0001 for all pairwise comparisons.
Table 3. Age Structure of the REACH-CHF Population From
1989 to 1999
Age in
Years Women Men Total
0–9 0 0 0
10–19 0 0 0
20–29 4 5 9
30–39 13 14 27
40–49 32 38 70
50–59 52 64 116
60–69 102 112 214
70–79 162 139 301
80–89 127 86 213
90–99 33 15 48
100–109 1 1 2
Counts are expressed per 1,000 REACH patients and rounded to the nearest whole
number.
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